Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Coloplast A/S    COLO B   DK0060448595


News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Coloplast A/S : 02/2017 Share buy-back programme

share with twitter share with LinkedIn share with facebook
share via e-mail
02/23/2017 | 07:17pm CET
Announcement No. 2/2017 23 February 2017 Coloplast initiates the second part of the DKK 1bn share buy-back programme

Coloplast A/S is initiating the second part of the share buy-back programme totalling up to DKK 1bn, cf. announcement no. 4/2016 of 16 February 2016. The second part of the programme of DKK 500 million will commence on 27 February 2017 and is expected to end by 28 August 2017. The first part of the programme, amounting to DKK 500 million, was executed in the 2015/16 fiscal year.

The buy-back programme is being launched within the authority granted by the shareholders at the Annual General Meeting on 5 December 2016, for the repurchase of up to 10% of the company's share capital.

The buy-back programme will be structured in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Regulation 2016/1052, also referred to as the "Safe Harbour" rules, which ensure that the company is protected against violation of insider legislation in connection with the buyback programme.

The company has entered into a contract with UBS, in which UBS agrees to act as manager of the second part of the buy-back programme for DKK 500 million, and purchase shares on behalf of Coloplast A/S. UBS has also agreed under the contract to make its trading decisions in relation to the shares in the company independently of, and without influence by, the company.

Coloplast is entitled to discontinue the repurchase during the life of the buy-back programme. If the company decides to discontinue the repurchase, such a decision will be disclosed to the public by announcement to Nasdaq Copenhagen. Once effective, UBS will no longer be entitled to purchase shares in Coloplast A/S on behalf of the company.

The second part of the buy-back programme is subject to the following terms:

  • The programme will commence on 27 February 2017 and is expected to end by 28 August 2017.

  • The volume of trading in own shares will be limited to a maximum total market value of DKK 500 million. Based on the current share price the approximate number of shares expected to be acquired under the buy-back programme is 1,016,000 B- shares, equivalent to 0.5% of the share capital of Coloplast A/S.

  • The maximum number of shares to be purchased in the company per daily market session will be the equivalent to 25% of the average volume of shares in the company traded on Nasdaq Copenhagen during the preceding 20 business days.

  • During the life of the buy-back programme no shares will be purchased at a price exceeding the higher of the following two prices:

  • the price of the last independent trade and

  • the highest current independent bid on Nasdaq Copenhagen.

Coloplast A/S Holtedam 1

3050 Humlebæk Denmark

Tel: +45 4911 1111

www.coloplast.com CVR-nr. 69749917

Details of transactions executed under the buy-back programme will be publicly disclosed on www.coloplast.com no later than the end of the seventh daily market session.

Prior to the launch of the share buy-back programme Coloplast'sholds 3,721,929 treasury shares, equal to 1.7% of the company's share capital.

Anders Lonning-Skovgaard CFO

For further information, please contact Investors and analysts

Ellen Bjurgert

Director, Investor Relations Tel. +45 4911 3376


Press and the media

Maria Lindeberg

Sr. Media Relations Manager, Corporate Communications Tel. +45 4911 3095


This announcement is available in a Danish and an English-language version. In the event of any discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2017-02 All rights reserved. Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology Care, Continence Care and Wound and Skin Care. We operate globally and employ around 11,000 people.

Coloplast A/S published this content on 23 February 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 23 February 2017 18:17:06 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on COLOPLAST A/S
02/23 COLOPLAST A/S : 02/2017 Share buy-back programme
02/21 Advanced Wound Management Market 2017 - 3M Health Care, Organogenesis, Molnly..
02/16 COLOPLAST A/S : Patent Issued for Package with a Spiral Space Configured for Sto..
02/09 COLOPLAST A/S : Patent Issued for Method and a Kit of Parts for Implanting a Pen..
02/09 COLOPLAST A/S : Patent Issued for Penile Prosthetic Pump Having an Inlet Valve w..
02/02 COLOPLAST A/S : Patent Issued for Method of Treating Urinary Incontinence (USPTO..
02/02 COLOPLAST A/S : Patent Issued for Implantable Devices for the Treatment of Incon..
02/02 COLOPLAST A/S : Patent Issued for Ostomy Bag with a Filter Construction (USPTO 9..
02/02 COLOPLAST A/S : Patent Issued for Manufacturing System for Processing a Web (USP..
02/01 COLOPLAST A/S : 01/2017 Q1 2016/17 Interim financial report
More news
Sector news : Medical Equipment Wholesale
02/21DJMEDTRONIC : Earnings Fall, Sales Rise -- Update
02/21 MEDTRONIC : sales, profit beat estimates; shares rise
02/21DJMEDTRONIC : Earnings Fall, Sales Rise
02/16 STRAUMANN : on hunt for 3D printer partner, could take stake - CEO
02/09 Smith & Nephew hurt by tough markets in China and Gulf states
More sector news : Medical Equipment Wholesale
News from SeekingAlpha
02/01 Coloplast ASB 2017 Q1 - Results - Earnings Call Slides
02/01 Coloplast's (CLPBF) CEO Lars Rasmussen on Q1 2016/17 Results - Earnings Call ..
02/01 Coloplast ASB beats on revenue
01/04 Political Ructions, Poor Deal-Making And Scandal - A Bad Year For Big-Cap Med..
2016 T-Rail Positions For 2018
Financials ( DKK)
Sales 2017 15 771 M
EBIT 2017 5 213 M
Net income 2017 3 944 M
Debt 2017 688 M
Yield 2017 2,86%
P/E ratio 2017 26,56
P/E ratio 2018 23,96
EV / Sales 2017 6,27x
EV / Sales 2018 5,83x
Capitalization 98 208 M
More Financials
Duration : Period :
Coloplast A/S Technical Analysis Chart | COLO B | DK0060448595 | 4-Traders
Full-screen chart
Technical analysis trends COLOPLAST A/S
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 21
Average target price 502  DKK
Spread / Average Target 1,3%
Consensus details
EPS Revisions
More Estimates Revisions
Lars Søren Rasmussen President & Chief Executive Officer
Michael Pram Rasmussen Chairman
Allan Rasmussen Executive Vice President-Global Operations
Anders Lonning-Skovgaard CFO, Executive VP & Head-Investor Relations
Oliver Johansen Senior VP-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
COLOPLAST A/S4.14%14 014
HENRY SCHEIN, INC.14.38%13 743
AMPLIFON SPA7.51%2 322
OWENS & MINOR, INC.2.78%2 214
More Results